TY - JOUR
T1 - Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles
T2 - Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
AU - Lipton, Richard B.
AU - Fanning, Kristina M.
AU - Buse, Dawn C.
AU - Martin, Vincent T.
AU - Reed, Michael L.
AU - Manack Adams, Aubrey
AU - Goadsby, Peter J.
N1 - Funding Information:
Financial Support: This study was supported by Allergan plc (Dublin, Ireland).
Funding Information:
Conflict of Interest: Richard B. Lipton, MD, serves on the editorial boards of Neurology and Cephalalgia and as senior advisor to Headache. He has received research support from the NIH. He also receives support from the Migraine Research Foundation and the National Headache Foundation. He has reviewed for the NIA and NINDS, and serves as consultant, advisory board member, or has received honoraria from Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Dr. Reddy’s Laboratories, electroCore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Novartis, Teva, and Vedanta. He receives royalties from Wolff’s Headache and Other Head Pain, 8th Edition, Oxford University Press, 2009, and Informa. He holds stock options in eNeura Therapeutics and Biohaven. Kristina M. Fanning, PhD, is an employee of Vedanta Research, which has received support funded by Allergan, Amgen, Dr. Reddy’s Laboratories, Eli Lilly, GlaxoSmithK-line, Merck & Co., Inc., and Novartis via grants to the National Headache Foundation. Vincent T. Martin, MD, in the past 12 months has been a consultant for Amgen, Alder, Avanir, and Supernaus, and a speaker for Allergan, Avanir, and Depomed. Michael L. Reed, PhD, is Managing Director of Vedanta Research, which has received research funding from Allergan, Amgen, Dr. Reddy’s Laboratories, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., and Novartis via grants to the National Headache Foundation. Vedanta Research has received funding directly from Allergan for work on the CaMEO Study. Aubrey Manack Adams, PhD, is a full-time employee of Allergan plc and owns stock in the company. Dawn C. Buse, PhD, has received grant support and honoraria from Allergan, Avanir, Eli Lilly, Teva, and Promius. She is on the editorial board of Current Pain and Headache Reports, The Journal of Headache and Pain, Pain Medicine News, and Pain Pathways magazine. Peter J. Goadsby, MD, PhD, has reported personal fees from Akita Biomedical and Alder Biopharmaceuticals, grants and personal fees from Amgen, and personal fees from Autonomic Technologies Inc., Avanir Pharma, Cipla Ltd, CoLucid Pharmaceuticals, Ltd., and Dr. Reddy’s Laboratories, grants and personal fees from Eli Lilly, personal fees from electroCore LLC, grants and personal fees from eNeura Inc., personal fees from Novartis, Pfizer Inc, Promius Pharma, Quest Diagnostics, Scion, Teva Pharmaceuticals, and Trigemina Inc., and personal fees from medico-legal work, Journal Watch, Up-to-Date, and Oxford University Press outside the submitted work. In addition, Dr. Goadsby has a magnetic stimulation patent for headache licensed to eNeura without fee.
Publisher Copyright:
© 2018 American Headache Society
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Objective: To identify natural subgroups of people with migraine based on profiles of comorbidities and concomitant conditions, hereafter referred to as comorbidities. Background: Migraine is a heterogeneous disease. Identifying natural subgroups (endophenotypes) may facilitate biological and genetic characterization and the development of personalized treatment. Methods: The Chronic Migraine Epidemiology and Outcomes Study is a prospective web-based survey study designed to characterize the course of migraine and related comorbidities in a systematic US sample of people with migraine. Respondents were asked if they ever had a specific comorbidity and, if present, whether the comorbidity was confirmed/diagnosed by a “doctor”; 62 comorbidities were available for analysis. Latent class analysis (LCA) modeling determined the optimal number of classes and a parsimonious set of comorbidities. Results: Of the 12,810 respondents with migraine, 11,837 reported ≥1 comorbidity and were included in this analysis. After statistical analysis and clinical judgment reduced the number of comorbidities, we selected an 8-class model based on 22 comorbidities. Each class had a distinct pattern summarized as follows: Class 1, Most Comorbidities; Class 2, Respiratory/Psychiatric; Class 3, Respiratory/Pain; Class 4, Respiratory; Class 5, Psychiatric; Class 6, Cardiovascular; Class 7, Pain; Class 8, Fewest Comorbidities. The distribution of individuals across models was variable, with one-third of respondents in Class 8 (Fewest Comorbidities) and <10% in Class 1 (Most Comorbidities). Demographic and headache characteristics, not used in assigning class membership, varied across classes. For example, comparing Class 1 (Most Comorbidities) and Class 8 (Fewest Comorbidities), Class 1 had a greater proportion of individuals with severe disability (Migraine Disability Assessment grade IV; 48.1% vs 22.3% of overall individuals) and higher rates of allodynia (67.6% vs 47.0%), medication overuse (36.4% vs 15.0%), chronic migraine (23.1% vs 9.1%), and aura (40.1% vs 28.8%). Conclusions: LCA modeling identified 8 natural subgroups of persons with migraine based on comorbidity profiles. These classes show differences in demographic and headache features not used to form the classes. Subsequent research will assess prognostic and biologic differences among the classes.
AB - Objective: To identify natural subgroups of people with migraine based on profiles of comorbidities and concomitant conditions, hereafter referred to as comorbidities. Background: Migraine is a heterogeneous disease. Identifying natural subgroups (endophenotypes) may facilitate biological and genetic characterization and the development of personalized treatment. Methods: The Chronic Migraine Epidemiology and Outcomes Study is a prospective web-based survey study designed to characterize the course of migraine and related comorbidities in a systematic US sample of people with migraine. Respondents were asked if they ever had a specific comorbidity and, if present, whether the comorbidity was confirmed/diagnosed by a “doctor”; 62 comorbidities were available for analysis. Latent class analysis (LCA) modeling determined the optimal number of classes and a parsimonious set of comorbidities. Results: Of the 12,810 respondents with migraine, 11,837 reported ≥1 comorbidity and were included in this analysis. After statistical analysis and clinical judgment reduced the number of comorbidities, we selected an 8-class model based on 22 comorbidities. Each class had a distinct pattern summarized as follows: Class 1, Most Comorbidities; Class 2, Respiratory/Psychiatric; Class 3, Respiratory/Pain; Class 4, Respiratory; Class 5, Psychiatric; Class 6, Cardiovascular; Class 7, Pain; Class 8, Fewest Comorbidities. The distribution of individuals across models was variable, with one-third of respondents in Class 8 (Fewest Comorbidities) and <10% in Class 1 (Most Comorbidities). Demographic and headache characteristics, not used in assigning class membership, varied across classes. For example, comparing Class 1 (Most Comorbidities) and Class 8 (Fewest Comorbidities), Class 1 had a greater proportion of individuals with severe disability (Migraine Disability Assessment grade IV; 48.1% vs 22.3% of overall individuals) and higher rates of allodynia (67.6% vs 47.0%), medication overuse (36.4% vs 15.0%), chronic migraine (23.1% vs 9.1%), and aura (40.1% vs 28.8%). Conclusions: LCA modeling identified 8 natural subgroups of persons with migraine based on comorbidity profiles. These classes show differences in demographic and headache features not used to form the classes. Subsequent research will assess prognostic and biologic differences among the classes.
KW - CaMEO
KW - chronic migraine
KW - comorbidities
UR - http://www.scopus.com/inward/record.url?scp=85050466340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050466340&partnerID=8YFLogxK
U2 - 10.1111/head.13342
DO - 10.1111/head.13342
M3 - Article
C2 - 30024028
AN - SCOPUS:85050466340
SN - 0017-8748
VL - 58
SP - 933
EP - 947
JO - Headache
JF - Headache
IS - 7
ER -